These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35686572)

  • 1. Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial.
    Wang XY; Mahmood SF; Jin F; Cheah WK; Ahmad M; Sohail MA; Ahmad W; Suppan VK; Sayeed MA; Luxmi S; Teo AH; Lee LY; Qi YY; Pei RJ; Deng W; Xu ZH; Yang JM; Zhang Y; Guan WX; Yu X
    Emerg Microbes Infect; 2022 Dec; 11(1):1910-1919. PubMed ID: 35686572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, and immunogenicity of SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012: a randomized, double-blind, placebo-controlled phase 3 trial.
    Zhou H; Zheng H; Peng Y; Su Y; Yu X; Wang W; Li S; Ding Y; Jiao S; Wang Y; Zhu X; Luo L; Dong Z; Liu L; Zhang F; Wu Q; Li J; Zhu F
    Front Immunol; 2024; 15():1407826. PubMed ID: 38903523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial.
    Wu JD; Li JX; Liu J; Wang HM; Zhou GH; Li J; Wu D; Chen X; Feng Y; Qi XY; Wang X; Gou JB; Ma TL; Yang XY; Xu LF; Wan P; Zhu T; Wang ZF; Zhu FC;
    Lancet Infect Dis; 2023 Sep; 23(9):1020-1030. PubMed ID: 37216958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
    Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V
    Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
    PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
    Zhou C; Qiu Y; Wang J; Zhong X; Zhu X; Huang X; Yang L; Ji Q; Zhou F; Wu S; Yang M; Zhang J; Liu K; Ji L; Yang H; Li C; Zhao Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2320913. PubMed ID: 38860446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
    Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
    Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
    Li JX; Hou LH; Gou JB; Yin ZD; Wu SP; Wang FZ; Zhang Z; Peng ZH; Zhu T; Shen HB; Chen W; Zhu FC;
    Lancet Infect Dis; 2023 Oct; 23(10):1143-1152. PubMed ID: 37352880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years.
    Gholami F; Hamidi Farahani R; Karimi Rahjerdi A; Ahi M; Sheidaei A; Gohari K; Rahimi Z; Ansarifar A; Basiri P; Moradi M; Jahangiri A; Naderi K; Ghasemi S; Khatami P; Honari M; Khodaverdloo S; Shooshtari M; Mehr Azin H; Moradi S; Shafaghi B; Allahyari H; Monazah A; Khodaei Poor A; Taghva Z; Bakhshande H; Karimi Nia M; Solaymani Dodaran M; Forooghizade M
    BMC Infect Dis; 2023 Feb; 23(1):118. PubMed ID: 36829111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.
    Tanriover MD; Doğanay HL; Akova M; Güner HR; Azap A; Akhan S; Köse Ş; Erdinç FŞ; Akalın EH; Tabak ÖF; Pullukçu H; Batum Ö; Şimşek Yavuz S; Turhan Ö; Yıldırmak MT; Köksal İ; Taşova Y; Korten V; Yılmaz G; Çelen MK; Altın S; Çelik İ; Bayındır Y; Karaoğlan İ; Yılmaz A; Özkul A; Gür H; Unal S;
    Lancet; 2021 Jul; 398(10296):213-222. PubMed ID: 34246358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial.
    Shu YJ; He JF; Pei RJ; He P; Huang ZH; Chen SM; Ou ZQ; Deng JL; Zeng PY; Zhou J; Min YQ; Deng F; Peng H; Zhang Z; Wang B; Xu ZH; Guan WX; Hu ZY; Zhang JK
    Chin Med J (Engl); 2021 Jul; 134(16):1967-1976. PubMed ID: 34310400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial.
    Zhang J; Hu Z; He J; Liao Y; Li Y; Pei R; Fang X; Zeng P; Fan R; Ou Z; Deng J; Zhou J; Guan W; Min Y; Deng F; Peng H; Zhang Z; Feng C; Xin B
    Emerg Microbes Infect; 2021 Dec; 10(1):1589-1597. PubMed ID: 34197281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial.
    Hannawi S; Saifeldin L; Abuquta A; Alamadi A; Mahmoud SA; Hassan A; Liu D; Yan L; Xie L
    EBioMedicine; 2023 Jan; 87():104386. PubMed ID: 36470077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi.
    Al Kaabi N; Yang Y; Eldin Hussein S; Yang T; Abdalla J; Wang H; Lou Z; Chinese Center For Disease Control And Prevention ; Bakkour A; Arafat A; China National Biotec Group Company Limited ; Jiang Z; Tian Y; National Engineering Technology Research Center For Combined Vaccines Wuhan Institute Of Biological Products Co Ltd ; Beijing Institute Of Biological Products Company Limited ; Xiao P; Zaher W; Eltantawy I; Wang C; Xu G; Zhang Y; Yang X
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.
    Xu JW; Wang BS; Gao P; Huang HT; Wang FY; Qiu W; Zhang YY; Xu Y; Gou JB; Yu LL; Liu X; Wang RJ; Zhu T; Hou LH; Wang Q
    Emerg Microbes Infect; 2024 Dec; 13(1):2281355. PubMed ID: 37933089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.